Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 Agonists for Physical and Vascular Health in Postmenopausal Women with Obesity
NCT07057310Phase 4Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide, tirzepatide in obesity, sponsored by Mayo Clinic. Started May 2025; status: enrolling by invitation.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07057310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057310.